Sugi Predict

Sugi Predict / Compounds / SCHEMBL646870

SCHEMBL646870

SCHEMBL646870

CC(C)(C)OC(=O)Nc1ccccc1CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.50
▸ HPGD P15428 2/20 0.50
▸ LMNA P02545 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.45
▸ BRD9 Q9H8M2 1/20 0.43
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ METAP1 P53582 1/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29729975 1.00 ALDH1A1 (0.50) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL13980716 0.89 POLB (0.50) ALDH1A1LMNAPOLBRXFP1MAPT
SCHEMBL29991524 0.89 POLB (0.50) ALDH1A1LMNAPOLBRXFP1MAPT
SCHEMBL1772002 0.88 LMNA (0.47) ALDH1A1LMNAPOLBRXFP1BRD9
SCHEMBL6595061 0.87 LMNA (0.49) ALDH1A1LMNAPOLBRXFP1BRD9
SCHEMBL3439958 0.86 ALDH1A1 (0.44) ALDH1A1HPGDLMNAPOLBRXFP1
SCHEMBL19924407 0.86 LMNA (0.48) ALDH1A1LMNAPOLBRXFP1BRD9
SCHEMBL646786 0.86 LMNA (0.48) ALDH1A1LMNAPOLBRXFP1BRD9
SCHEMBL5766 0.86 LMNA (0.48) ALDH1A1LMNAPOLBRXFP1BRD9
SCHEMBL1127904 0.86 LMNA (0.48) ALDH1A1LMNAPOLBRAB9ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037358-B2 Compositions comprising reversibly modified oligonucleotides and uses thereof DICERNA PHARMACEUTICALS, INC. (US) 2024-07-16 — — US disclosed
US-12037358-B2 Compositions comprising reversibly modified oligonucleotides and uses thereof DICERNA PHARMACEUTICALS, INC. (US) 2024-07-16 — — US disclosed
EP-3503730-B1 COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF DICERNA PHARMACEUTICALS INC (US) 2023-09-27 — — EP disclosed
EP-2844345-B1 MODULATORS OF THE RELAXIN RECEPTOR 1 US HEALTH (US) 2022-08-03 — — EP disclosed
US-10550084-B2 Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same ARBUTUS BIOPHARMA CORPORATION (CA) 2020-02-04 — — US disclosed
US-10550084-B2 Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same ARBUTUS BIOPHARMA CORPORATION (CA) 2020-02-04 — — US disclosed
CN-109890207-A COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF 迪克纳制药公司 2019-06-14 — — CN disclosed
US-20190169128-A1 SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2019-06-06 — — US disclosed
US-20190169128-A1 SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2019-06-06 — — US disclosed
US-10202378-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-02-12 — — US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 — — US disclosed
EP-1212327-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2002-06-12 — — EP disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 — — US disclosed
CN-1075808-C Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 2001-12-05 — — CN disclosed
CN-1310169-A Anils with nitric oxide synzyme inhibiting function SHUGAI SEIYAKU K K (JP) 2001-08-29 — — CN disclosed
WO-2001019829-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2001-03-22 — — WO disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 — — EP disclosed
US-5719141-A HYPOTENSIVE AGENTS NOVARTIS CORPORATION (US) 1998-02-17 — — US disclosed
WO-1998004535-A1 A PRACTICAL SYNTHESIS OF BENZOXAZINONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1998-02-05 — — WO disclosed
CN-1172473-A Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 1998-02-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB ALDH1A1 3599/4885HPGD 2640/4885LMNA 1318/4885
US-10550084-B2 Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same RNASEH1, RNASE1, RNASEL ALDH1A1 1249/4885HPGD 1044/4885LMNA 281/4885
US-10202378-B2 Therapeutic compounds and uses thereof TAF1, TAF1L, TAF1B ALDH1A1 2132/4885HPGD 3896/4885LMNA 3466/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 ALDH1A1 3941/4885HPGD 2890/4885LMNA 1288/4885
US-20190169128-A1 SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME RNASEH1, RNASE1, RNASEL ALDH1A1 1249/4885HPGD 1044/4885LMNA 281/4885
US-12037358-B2 Compositions comprising reversibly modified oligonucleotides and uses thereof GSS, GSR, RNMT ALDH1A1 1098/4885HPGD 560/4885LMNA 3681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.